MCID: RHB003
MIFTS: 61

Rhabdomyosarcoma

Categories: Rare diseases, Genetic diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Rhabdomyosarcoma

MalaCards integrated aliases for Rhabdomyosarcoma:

Name: Rhabdomyosarcoma 12 72 55 28 51 41 14 69

Characteristics:

Orphanet epidemiological data:

55
rhabdomyosarcoma
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/1000000 (Europe); Age of onset: Childhood;

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3247
MeSH 41 D012208
NCIt 46 C3359
Orphanet 55 ORPHA780
MESH via Orphanet 42 D012208
UMLS via Orphanet 70 C0035412
ICD10 via Orphanet 33 C49.9
UMLS 69 C0035412

Summaries for Rhabdomyosarcoma

Disease Ontology : 12 A skeletal muscle cancer that arise from skeletal muscle progenitors.

MalaCards based summary : Rhabdomyosarcoma is related to parameningeal embryonal rhabdomyosarcoma and botryoid rhabdomyosarcoma. An important gene associated with Rhabdomyosarcoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Endometrial cancer and PI3K-Akt signaling pathway. The drugs Cyclophosphamide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and skeletal muscle, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 72 Rhabdomyosarcoma, or RMS, is an aggressive and highly malignant form of cancer that develops from... more...

Related Diseases for Rhabdomyosarcoma

Diseases in the Rhabdomyosarcoma family:

Rhabdomyosarcoma 2

Diseases related to Rhabdomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 322)
# Related Disease Score Top Affiliating Genes
1 parameningeal embryonal rhabdomyosarcoma 34.1 ALK TP53
2 botryoid rhabdomyosarcoma 34.0 DICER1 FOXO1 MB MYOD1 PAX3
3 spindle cell rhabdomyosarcoma 34.0 MB MYOD1
4 embryonal rhabdomyosarcoma 34.0 DICER1 FOXO1 IGF2 MB MYOD1 PAX3
5 breast rhabdomyosarcoma 33.9 MB MYOD1
6 pleomorphic rhabdomyosarcoma 33.9 FOXO1 MB MYOD1 PAX3 PAX7
7 rhabdomyosarcoma 2 33.8 ALK FOXO1 MB MDM2 MYOD1 PAX3
8 beckwith-wiedemann syndrome 32.6 IGF2 MYOD1 SLC22A18 STIM1 TP53
9 malignant triton tumor 32.2 MB MYOD1
10 li-fraumeni syndrome 32.0 BRCA1 MDM2 TP53
11 soft tissue sarcoma 31.2 FOXO1 MDM2 TP53
12 cervical polyp 30.5 FHL2 MYOD1
13 liposarcoma 30.4 MB MDM2 TP53
14 embryonal sarcoma 30.4 MDM2 MYOD1 TP53
15 leiomyosarcoma 30.4 IGF2 MB MDM2 TP53
16 pleuropulmonary blastoma 30.4 DICER1 MB TP53
17 blastoma 30.4 DICER1 IGF2 TP53
18 mesenchymoma 30.4 MB MDM2 MYOD1
19 medullomyoblastoma 30.3 MB MYOD1 TP53
20 malignant mesenchymoma 30.1 MB MDM2 MYOD1 TP53
21 muscular dystrophy, duchenne type 30.1 MB MYOD1 TTN
22 inflammatory myofibroblastic tumor 30.1 ALK MDM2 TP53
23 ewing sarcoma 30.0 ALK FOXO1 IGF2 MDM2 MYOD1 PAX3
24 undifferentiated embryonal sarcoma of the liver 30.0 MDM2 MYOD1
25 alveolar soft part sarcoma 29.9 MB MYF6 MYOD1
26 diffuse large b-cell lymphoma 29.8 ALK MDM2 TP53
27 myositis 29.8 MB MYOD1 TTN
28 histiocytoma 29.6 ALK MB MDM2 MYOD1 TP53
29 rhabdomyosarcoma, embryonal, 1 12.4
30 prostate rhabdomyosarcoma 12.2
31 prostate embryonal rhabdomyosarcoma 12.2
32 liver rhabdomyosarcoma 12.2
33 rhabdomyosarcoma, embryonal, 2 12.2
34 orbit rhabdomyosarcoma 12.0
35 bile duct rhabdomyosarcoma 12.0
36 mediastinum rhabdomyosarcoma 12.0
37 anus rhabdomyosarcoma 12.0
38 orbit embryonal rhabdomyosarcoma 12.0
39 central nervous system rhabdomyosarcoma 11.9
40 gallbladder rhabdomyosarcoma 11.9
41 orbit alveolar rhabdomyosarcoma 11.9
42 rhabdomyosarcoma of the cervix uteri 11.9
43 vulvovaginal rhabdomyosarcoma 11.9
44 rhabdomyosarcoma of the corpus uteri 11.9
45 mixed type rhabdomyosarcoma 11.8
46 childhood pleomorphic rhabdomyosarcoma 11.8
47 embryonal extrahepatic bile duct rhabdomyosarcoma 11.8
48 rectum rhabdomyosarcoma 11.8
49 ovary rhabdomyosarcoma 11.8
50 testis rhabdomyosarcoma 11.8

Graphical network of the top 20 diseases related to Rhabdomyosarcoma:



Diseases related to Rhabdomyosarcoma

Symptoms & Phenotypes for Rhabdomyosarcoma

GenomeRNAi Phenotypes related to Rhabdomyosarcoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 PAX3 PAX7 SLC22A18 TP53 BRCA1 FOXO1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 PAX3 PAX7 SLC22A18 TP53 BRCA1 FOXO1

MGI Mouse Phenotypes related to Rhabdomyosarcoma:

43 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.45 STIM1 TTN TP53 MB MYF6 MDM2
2 cardiovascular system MP:0005385 10.43 STIM1 TTN TP53 MB MDM2 IGF2
3 homeostasis/metabolism MP:0005376 10.43 TP53 STIM1 TTN MB MYF6 MDM2
4 behavior/neurological MP:0005386 10.4 TP53 TTN IGF2 MDM2 FOXO1 FOXO3
5 cellular MP:0005384 10.39 TTN PAX7 TP53 STIM1 MB IGF2
6 mortality/aging MP:0010768 10.39 TP53 STIM1 TTN MB MYF6 MDM2
7 embryo MP:0005380 10.37 TTN TP53 MYF6 MDM2 MB IGF2
8 immune system MP:0005387 10.33 PAX7 TP53 STIM1 TTN IGF2 MDM2
9 endocrine/exocrine gland MP:0005379 10.32 TP53 MDM2 FOXO1 IGF2 FOXO3 ALK
10 hematopoietic system MP:0005397 10.31 PAX7 TP53 STIM1 MB IGF2 MDM2
11 integument MP:0010771 10.28 STIM1 TP53 MDM2 FOXO1 IGF2 FOXO3
12 muscle MP:0005369 10.27 TTN TP53 MYF6 MDM2 MYOD1 MB
13 neoplasm MP:0002006 10.22 TP53 MYF6 MDM2 MYOD1 FOXO3 FOXO1
14 craniofacial MP:0005382 10.21 TP53 TTN MDM2 FOXO1 IGF2 DICER1
15 digestive/alimentary MP:0005381 10.2 PAX7 TP53 IGF2 MDM2 FOXO3 FOXO1
16 nervous system MP:0003631 10.2 PAX7 TP53 STIM1 IGF2 MDM2 FOXO3
17 normal MP:0002873 10.18 TTN TP53 MYF6 MDM2 FHL2 FOXO1
18 no phenotypic analysis MP:0003012 10.09 TP53 MYF6 MDM2 FOXO1 IGF2 DICER1
19 limbs/digits/tail MP:0005371 10.07 TP53 IGF2 MDM2 FOXO1 DICER1 BRCA1
20 reproductive system MP:0005389 9.96 TP53 IGF2 MDM2 FOXO1 FOXO3 BRCA1
21 respiratory system MP:0005388 9.93 STIM1 TP53 MYF6 MYOD1 MB IGF2
22 renal/urinary system MP:0005367 9.92 TP53 IGF2 MDM2 FOXO3 DICER1 BRCA1
23 skeleton MP:0005390 9.86 STIM1 TTN TP53 MYF6 MDM2 MYOD1
24 pigmentation MP:0001186 9.85 TP53 MDM2 FOXO3 BRCA1 ALK PAX3
25 vision/eye MP:0005391 9.32 TP53 STIM1 TTN MYF6 IGF2 FOXO3

Drugs & Therapeutics for Rhabdomyosarcoma

Drugs for Rhabdomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 275)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
5 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
10
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
11
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
12
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
13
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
14
Morphine Approved, Investigational Phase 3,Phase 1,Phase 2 57-27-2 5288826
15
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
16
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
17
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 44424639 60780
18
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
19
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
20
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
21
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
22
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
23
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
24
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
25
Captopril Approved Phase 3 62571-86-2 44093
26
Palivizumab Approved, Investigational Phase 3 188039-54-5
27
Ribavirin Approved Phase 3 36791-04-5 37542
28
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
29
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
30
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
31
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1 3375-50-6 598
32
Idarubicin Approved Phase 3 58957-92-9 42890
33
Cyproheptadine Approved Phase 3 129-03-3 2913
34
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
35
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
36
Mycophenolic acid Approved Phase 3 24280-93-1 446541
37
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
38
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
39 Trofosfamide Investigational Phase 3 22089-22-1
40 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antimitotic Agents Phase 3,Phase 2,Phase 1
42 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
43 Etoposide phosphate Phase 3,Phase 2,Phase 1
44 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
45 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
46 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
47 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
48 Antifungal Agents Phase 3,Phase 2,Phase 1
49 Antimetabolites Phase 3,Phase 2,Phase 1
50 Hormone Antagonists Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 265)

# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
3 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
4 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
5 Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
6 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
7 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
8 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
9 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
10 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
11 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
12 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
13 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
14 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
15 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
16 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
17 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
18 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
19 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
20 Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma Recruiting NCT02567435 Phase 3 Cyclophosphamide;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate
21 Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma Recruiting NCT00876031 Phase 3 trofosfamide, idarubicin, etoposide
22 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Active, not recruiting NCT00075582 Phase 3 dactinomycin;cyclophosphamide;vincristine sulfate
23 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Active, not recruiting NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
24 Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood Terminated NCT00162695 Phase 3 Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide
25 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
26 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
27 Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma Unknown status NCT00245089 Phase 2 cyclophosphamide;vincristine sulfate
28 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma Unknown status NCT00245141 Phase 2 cyclophosphamide;vincristine sulfate
29 Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas Unknown status NCT01216839 Phase 2 Everolimus
30 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
31 Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
32 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
33 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
34 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
35 Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma Completed NCT00055939 Phase 2 exatecan mesylate
36 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
37 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Completed NCT01222715 Phase 2 Cyclophosphamide;Temsirolimus;Vinorelbine Tartrate
38 Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma Completed NCT00025363 Phase 2 vincristine sulfate;irinotecan hydrochloride;cyclophosphamide;doxorubicin hydrochloride;ifosfamide;etoposide;tirapazamine
39 Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Completed NCT01055314 Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Irinotecan Hydrochloride;Temozolomide;Vincristine Sulfate Liposome
40 New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma Completed NCT00001335 Phase 2 ADR-529;Topotecan;G-CSF
41 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma Completed NCT00003955 Phase 2 cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
42 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
43 Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone Completed NCT00006234 Phase 1, Phase 2
44 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
45 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Completed NCT00070109 Phase 2 trabectedin
46 A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Completed NCT00001566 Phase 2 indinavir sulfate
47 A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Completed NCT00001564 Phase 2 EF-1 Peptide;EF-2 Peptide;PXFK Peptide;E7 Peptide;IL-2;IL-4;GM-CSF;CD40 Ligand
48 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
49 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
50 Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors Completed NCT00106353 Phase 1, Phase 2 Torisel

Search NIH Clinical Center for Rhabdomyosarcoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: rhabdomyosarcoma

Genetic Tests for Rhabdomyosarcoma

Genetic tests related to Rhabdomyosarcoma:

# Genetic test Affiliating Genes
1 Rhabdomyosarcoma 28

Anatomical Context for Rhabdomyosarcoma

MalaCards organs/tissues related to Rhabdomyosarcoma:

38
Bone, Bone Marrow, Skeletal Muscle, Prostate, Cervix, Brain, Nk Cells

Publications for Rhabdomyosarcoma

Articles related to Rhabdomyosarcoma:

(show top 50) (show all 2054)
# Title Authors Year
1
Congenital embryonal rhabdomyosarcoma caused by heterozygous concomitant PTCH1 and PTCH2 germline mutations. ( 29230040 )
2018
2
Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors. ( 29316425 )
2018
3
NRAS-mutated rhabdomyosarcoma cells are vulnerable to mitochondrial apoptosis induced by co-inhibition of MEK and PI3KI+. ( 29437705 )
2018
4
More than Grapes and Bleeding: An Updated Look at Pelvic Rhabdomyosarcoma in Young Females. ( 29421342 )
2018
5
Rhabdomyosarcoma of the Head and Neck: A Multimodal Approach. ( 29404242 )
2018
6
Vision loss secondary to orbital extension of rhabdomyosarcoma in an adult. ( 29424955 )
2018
7
Uterine Rhabdomyosarcoma in Adults. ( 29320751 )
2018
8
PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. ( 29367756 )
2018
9
Phacomatosis pigmentokeratotica: a case of HRAS mosaicism causing rhabdomyosarcoma. ( 29430633 )
2018
10
Evaluation of Trace Elements in Augmentation of Statin-Induced Cytotoxicity in Uremic Serum-Exposed Human Rhabdomyosarcoma Cells. ( 29370118 )
2018
11
Lumbar Intraspinal Spindle Cell Rhabdomyosarcoma as a Rare Cause of Spinal Stenosis: A Case Report. ( 29452297 )
2018
12
Rhabdomyosarcoma Revealed by a Breast Metastasis. ( 29356738 )
2018
13
SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma. ( 29445192 )
2018
14
Extracellular cholesterol oxidase production by Streptomyces aegyptia, in vitro anticancer activities against rhabdomyosarcoma, breast cancer cell-lines and in vivo apoptosis. ( 29426900 )
2018
15
HNRNPH1 is required for rhabdomyosarcoma cell growth and survival. ( 29362363 )
2018
16
Fusion-Negative Rhabdomyosarcoma Can Arise from Endothelial Cells. ( 29352048 )
2018
17
Importance of whole-body imaging with complete coverage of hands and feet in alveolar rhabdomyosarcoma staging. ( 29368010 )
2018
18
Molecular diagnostics in the management of rhabdomyosarcoma. ( 28058850 )
2017
19
Spindle cell/sclerosing rhabdomyosarcoma with intracranial invasion without destroying the bone of the skull base: a case report and literature review. ( 28839951 )
2017
20
Suicide gene therapy of rhabdomyosarcoma. ( 28035376 )
2017
21
Sertoli-Leydig Cell Tumor with Concurrent Rhabdomyosarcoma: Three Case Reports and a Review of the Literature. ( 28751916 )
2017
22
Congenital embryonal rhabdomyosarcoma; multiple lesions. ( 28103501 )
2017
23
Successful treatment of adult pleomorphic rhabdomyosarcoma with bone invasion in the lower leg by chemotherapy and biological reconstruction: A case report. ( 28356215 )
2017
24
When Chemotherapy Is Not Enough-Management of Prostatic Embryonal Rhabdomyosarcoma in an Infant. ( 29155187 )
2017
25
Mandibular embryonal rhabdomyosarcoma with cartilaginous metaplasia: report of a case and review of literature. ( 29029988 )
2017
26
Matrine inhibits cell proliferation and induces apoptosis of human rhabdomyosarcoma cells via downregulation of the extracellular signal-regulated kinase pathway. ( 28927059 )
2017
27
A case report of concurrent embryonal rhabdomyosarcoma and diffuse large B-cell lymphoma in an adult without identifiable cancer predisposition. ( 28194276 )
2017
28
Re: Paratesticular Rhabdomyosarcoma: Importance of Initial Therapy. ( 28905768 )
2017
29
Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. ( 29100276 )
2017
30
Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands. ( 28881358 )
2017
31
EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma. ( 28817624 )
2017
32
Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines. ( 28739691 )
2017
33
Rhabdomyosarcoma mimicking as pleural effusion. ( 29417036 )
2017
34
Clinicopathological analysis of concomitant hepatic embryonal rhabdomyosarcoma and hepatocellular carcinoma. ( 28554759 )
2017
35
Co-occurrence of rhabdomyosarcoma and Mowat-Wilson syndrome: is there a connection? ( 28230647 )
2017
36
Embryonal Rhabdomyosarcoma of the Cervix: A Rare Disease at an Uncommon Age. ( 29375950 )
2017
37
Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. ( 28985758 )
2017
38
Pleomorphic rhabdomyosarcoma infiltrating thoracic spine in a 59-year-old female patient: Case report. ( 28868225 )
2017
39
Local control for vaginal botryoid rhabdomyosarcoma with prerectal transperineal surgical resection and autologous buccal graft vaginal replacement: A novel, minimally invasive, radiation-sparing approach. ( 29258699 )
2017
40
Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient. ( 28421158 )
2017
41
Very Long-term Sequelae After Nonradical Surgery Combined With Brachytherapy in an Infant With a Chemotherapy-resistant Rhabdomyosarcoma of the Tongue. ( 28859029 )
2017
42
A pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma. ( 27986986 )
2017
43
NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma. ( 28380437 )
2017
44
PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. ( 28138962 )
2017
45
Intrathoracic Rhabdomyosarcoma With Mediastinal Shift. ( 28935335 )
2017
46
Pulsed-dose rate brachytherapy for pediatric bladder prostate rhabdomyosarcoma: Compliance and early clinical results. ( 28760484 )
2017
47
Wandering Pelvic Mass: Rhabdomyosarcoma of the Meckel Diverticulum. ( 28284478 )
2017
48
Sequencing of DICER1 in sarcomas identifies biallelic somatic DICER1 mutations in an adult-onset embryonal rhabdomyosarcoma. ( 28524158 )
2017
49
Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma. ( 28080960 )
2017
50
NFI_B signaling in alveolar rhabdomyosarcoma. ( 28883017 )
2017

Variations for Rhabdomyosarcoma

ClinVar genetic disease variations for Rhabdomyosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BRCA1 NM_007294.3(BRCA1): c.844_850dupTCATTAC (p.Gln284Leufs) duplication Pathogenic rs80357989 GRCh37 Chromosome 17, 41246698: 41246704
2 ALK NM_004304.4(ALK): c.3673G> A (p.Asp1225Asn) single nucleotide variant Pathogenic rs1057519696 GRCh37 Chromosome 2, 29436920: 29436920
3 FGFR4 NM_213647.2(FGFR4): c.1605C> A (p.Asn535Lys) single nucleotide variant Likely pathogenic rs1057519792 GRCh37 Chromosome 5, 176522416: 176522416
4 FGFR4 NM_213647.2(FGFR4): c.1605C> G (p.Asn535Lys) single nucleotide variant Likely pathogenic rs1057519792 GRCh37 Chromosome 5, 176522416: 176522416
5 FGFR4 NM_213647.2(FGFR4): c.1649T> A (p.Val550Glu) single nucleotide variant Likely pathogenic rs1057519793 GRCh37 Chromosome 5, 176522552: 176522552

Cosmic variations for Rhabdomyosarcoma:

9 (show top 50) (show all 64)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM45253 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.611A>G p.E204G 6
2 COSM45255 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.668C>G p.P223R 6
3 COSM10660 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.818G>A p.R273H 6
4 COSM45256 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.871A>C p.K291Q 6
5 COSM45005 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.739A>G p.N247D 6
6 COSM11081 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.733G>T p.G245C 6
7 COSM10813 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.394A>G p.K132E 6
8 COSM44536 TP53 soft tissue,striated muscle,rhabdomyosarcoma,NS c.728T>C p.M243T 6
9 COSM13014 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,NS c.214G>A p.A72T 6
10 COSM13013 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,NS c.205G>A p.E69K 6
11 COSM13016 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,NS c.226G>C p.E76Q 6
12 COSM14271 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,NS c.1508G>T p.G503V 6
13 COSM1235326 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,NS c.3023C>T p.S1008F 6
14 COSM766 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,NS c.1636C>A p.Q546K 6
15 COSM763 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,NS c.1633G>A p.E545K 6
16 COSM760 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,NS c.1624G>A p.E542K 6
17 COSM775 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,NS c.3140A>G p.H1047R 6
18 COSM762 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,NS c.1625A>T p.E542V 6
19 COSM580 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.181C>A p.Q61K 6
20 COSM585 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.183A>T p.Q61H 6
21 COSM574 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.38G>T p.G13V 6
22 COSM584 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.182A>G p.Q61R 6
23 COSM564 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.35G>A p.G12D 6
24 COSM586 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.183A>C p.Q61H 6
25 COSM562 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.34G>T p.G12C 6
26 COSM569 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.37G>C p.G13R 6
27 COSM563 NRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.34G>A p.G12S 6
28 COSM1745010 MYOD1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.365T>G p.L122R 6
29 COSM528 KRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.37G>A p.G13S 6
30 COSM553 KRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.182A>T p.Q61L 6
31 COSM516 KRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.34G>T p.G12C 6
32 COSM521 KRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.35G>A p.G12D 6
33 COSM532 KRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.38G>A p.G13D 6
34 COSM522 KRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.35G>C p.G12A 6
35 COSM496 HRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.181C>A p.Q61K 6
36 COSM486 HRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.37G>C p.G13R 6
37 COSM481 HRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.34G>T p.G12C 6
38 COSM483 HRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.35G>T p.G12V 6
39 COSM480 HRAS soft tissue,striated muscle,rhabdomyosarcoma,NS c.34G>A p.G12S 6
40 COSM5702570 FGFR1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.1611G>T p.M537I 6
41 COSM5702566 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.2809C>T p.R937C 6
42 COSM3738459 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.5437G>A p.E1813K 6
43 COSM959251 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.5113G>A p.E1705K 6
44 COSM3744763 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.5428G>T p.D1810Y 6
45 COSM3738451 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.5439G>T p.E1813D 6
46 COSM3738549 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.5365-1G>T p.? 6
47 COSM959249 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.5125G>A p.D1709N 6
48 COSM393242 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.2062C>T p.R688* 6
49 COSM4169595 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.5425G>A p.G1809R 6
50 COSM5692 CTNNB1 soft tissue,striated muscle,rhabdomyosarcoma,NS c.134C>A p.S45Y 6

Copy number variations for Rhabdomyosarcoma from CNVD:

7 (show all 19)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 32214 1 34600000 40100000 Amplification MYCL1 Rhabdomyosarcoma
2 48341 11 1 2800000 Loss HRAS Rhabdomyosarcoma
3 55467 11 532242 535550 Mutation HRAS Rhabdomyosarcoma
4 69397 12 54900000 58100000 Amplification or los s GLI Rhabdomyosarcoma
5 69949 12 56600000 58100000 Amplification CDK4 Rhabdomyosarcoma
6 69950 12 56600000 58100000 Amplification SAS Rhabdomyosarcoma
7 79876 13 79000000 101700000 Amplification C13orf25 Rhabdomyosarcoma
8 79877 13 79000000 101700000 Amplification GPC5 Rhabdomyosarcoma
9 106840 17 1 3300000 Loss HIC1 Rhabdomyosarcoma
10 106842 17 1 3300000 Loss Rhabdomyosarcoma
11 106969 17 10700000 22200000 Loss Rhabdomyosarcoma
12 110141 17 314735 515143 Loss Rhabdomyosarcoma
13 127361 19 32400000 43400000 Amplification AKT2 Rhabdomyosarcoma
14 185187 4 187100000 191154276 Loss Rhabdomyosarcoma
15 187611 4 52700000 59500000 Loss PDGFRA Rhabdomyosarcoma
16 187815 4 55095264 55146925 Amplificationlicatio n PDGFRA Rhabdomyosarcoma
17 187856 4 55524095 55606879 Amplificationlicatio n C-Kit Rhabdomyosarcoma
18 239020 8 36500000 45600000 Amplification FGFR1 Rhabdomyosarcoma
19 253524 9 43600000 47300000 Loss Rhabdomyosarcoma

Expression for Rhabdomyosarcoma

Search GEO for disease gene expression data for Rhabdomyosarcoma.

Pathways for Rhabdomyosarcoma

Pathways related to Rhabdomyosarcoma according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.95 ALK BRCA1 FOXO1 FOXO3 MDM2 TP53
2
Show member pathways
12.86 BRCA1 FOXO1 FOXO3 IGF2 MDM2 TP53
3 12.66 ALK FOXO1 IGF2 MDM2 NCOA1 TP53
4
Show member pathways
12.62 FOXO1 FOXO3 MDM2 STIM1 TP53
5
Show member pathways
12.31 FOXO3 IGF2 MDM2 TP53
6
Show member pathways
12.14 FOXO1 FOXO3 MDM2 TP53
7 12.03 FOXO1 FOXO3 MDM2 TP53
8 11.98 BRCA1 FOXO1 MDM2 TP53
9 11.92 FOXO1 MDM2 PAX3 PAX7 TP53
10 11.8 MYOD1 PAX3 PAX7
11 11.8 FOXO1 FOXO3 MYOD1
12 11.8 FOXO1 MDM2 NCOA1 TP53
13 11.78 FOXO1 FOXO3 MDM2
14
Show member pathways
11.75 BRCA1 MDM2 TP53
15
Show member pathways
11.73 FOXO1 FOXO3 MDM2
16 11.71 MDM2 NCOA1 TP53
17 11.71 FOXO1 IGF2 MDM2 TP53
18 11.68 FOXO1 FOXO3 TP53
19 11.64 BRCA1 MDM2 TP53
20 11.57 BRCA1 FOXO3 TP53
21 11.51 FOXO1 FOXO3 MYOD1 NCOA1
22 11.49 MDM2 MYOD1 PAX3
23 11.46 MDM2 NCOA1 TP53
24 11.41 FOXO1 MDM2 NCOA1
25 11.35 BRCA1 MDM2 TP53
26 11.31 BRCA1 FHL2 FOXO1 MDM2 NCOA1
27 11.3 BRCA1 MDM2 TP53
28 11.19 FOXO1 FOXO3 MDM2 TP53
29 11.07 BRCA1 MDM2 TP53
30 10.65 FOXO1 FOXO3
31 10.61 FHL2 FOXO1 FOXO3 MYOD1 TP53

GO Terms for Rhabdomyosarcoma

Cellular components related to Rhabdomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.65 BRCA1 FHL2 FOXO1 FOXO3 MDM2 MYF6
2 protein complex GO:0043234 9.1 ALK BRCA1 MDM2 NCOA1 STIM1 TP53

Biological processes related to Rhabdomyosarcoma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.99 FHL2 FOXO1 MDM2 PAX7 TP53
2 regulation of transcription by RNA polymerase II GO:0006357 9.95 BRCA1 FHL2 FOXO1 FOXO3 MYF6 MYOD1
3 negative regulation of transcription, DNA-templated GO:0045892 9.93 BRCA1 FHL2 FOXO1 MDM2 MYF6 TP53
4 negative regulation of transcription by RNA polymerase II GO:0000122 9.91 DICER1 FHL2 FOXO1 FOXO3 IGF2 MDM2
5 skeletal muscle tissue development GO:0007519 9.7 MYF6 MYOD1 PAX7
6 transcription by RNA polymerase II GO:0006366 9.7 BRCA1 FOXO3 MYF6 MYOD1 NCOA1 PAX3
7 protein kinase B signaling GO:0043491 9.69 FOXO1 FOXO3 MDM2
8 androgen receptor signaling pathway GO:0030521 9.67 BRCA1 FHL2 NCOA1
9 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.62 BRCA1 TP53
10 DNA damage response, signal transduction by p53 class mediator GO:0030330 9.61 FOXO3 TP53
11 regulation of gene expression by genetic imprinting GO:0006349 9.61 BRCA1 IGF2
12 positive regulation of transcription by RNA polymerase II GO:0045944 9.61 BRCA1 FOXO1 FOXO3 MYF6 MYOD1 NCOA1
13 myotube differentiation GO:0014902 9.58 MYOD1 STIM1
14 enamel mineralization GO:0070166 9.58 FOXO1 STIM1
15 regulation of neural precursor cell proliferation GO:2000177 9.57 FOXO1 FOXO3
16 positive regulation of skeletal muscle fiber development GO:0048743 9.56 MYF6 MYOD1
17 muscle organ development GO:0007517 9.56 MYF6 MYOD1 PAX3 PAX7
18 muscle tissue morphogenesis GO:0060415 9.55 MYF6 PAX7
19 muscle cell fate commitment GO:0042693 9.54 MYF6 MYOD1
20 cellular response to actinomycin D GO:0072717 9.43 MDM2 TP53
21 response to water-immersion restraint stress GO:1990785 9.4 FOXO3 MDM2
22 positive regulation of transcription, DNA-templated GO:0045893 9.28 BRCA1 FHL2 FOXO1 FOXO3 MYF6 MYOD1
23 transcription, DNA-templated GO:0006351 10.25 BRCA1 FHL2 FOXO1 FOXO3 MYOD1 NCOA1
24 regulation of transcription, DNA-templated GO:0006355 10.06 BRCA1 FHL2 FOXO1 FOXO3 IGF2 MYF6

Molecular functions related to Rhabdomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding transcription factor activity GO:0003700 9.95 FOXO1 FOXO3 MYF6 MYOD1 PAX3 PAX7
2 sequence-specific DNA binding GO:0043565 9.8 FOXO1 FOXO3 MYOD1 PAX3 PAX7 TP53
3 transcription coactivator activity GO:0003713 9.78 BRCA1 FHL2 MYOD1 NCOA1
4 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding GO:0001228 9.67 FOXO3 MYF6 MYOD1 TP53
5 transcription factor binding GO:0008134 9.55 FHL2 FOXO1 MYOD1 NCOA1 TP53
6 transcription cofactor binding GO:0001221 9.43 FOXO3 TP53
7 androgen receptor binding GO:0050681 9.43 BRCA1 FHL2 NCOA1
8 enzyme binding GO:0019899 9.43 BRCA1 MDM2 MYOD1 NCOA1 TP53 TTN
9 ubiquitin protein ligase binding GO:0031625 9.1 BRCA1 FOXO1 MDM2 MYOD1 SLC22A18 TP53
10 DNA binding GO:0003677 10.11 BRCA1 DICER1 FOXO1 FOXO3 MYF6 MYOD1

Sources for Rhabdomyosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....